MIT'S PROGRAM ON THE PHARMACEUTICAL INDUSTRY

Annual Report of Research and Educational Programs
1996

Appendix B. POPI-Supported Students

DOCTORAL STUDENTS

Name

Department

Grad.
Date

Thesis Topic/Interest

Position
Alan Afuah Sloan School 1995Strategic management of pharmaceutical R&DUniv. of Michigan
Frank Basa Sloan School 1995 Pharmaceutical industry project management consulting
Linda Bui Economics 1993Measuring health outcomes-adjusted pharmaceutical price changes Boston Univ.
Dept. of Economics
Bart ClarysseSloan School1996Pharmaceutical industry structureacademic position in Belgium
Gillian Currie Economics (Yale) 1998 Economics of antidepressant medicines
Rebecca D'Amato Operations Research1998Outcomes research
Christopher Dowd Chemical Engineering 1997 Growth factor transport through basement membrane
Morten Engel Chemical Engineering 1999 Benchmarking the manufacture of pharmaceuticals
Varghese George Sloan School 1996 Interfirm relationships in the pharmaceutical industry Rutgers Univ.
Arni Hauksson Operations Research 1997 Outcomes research
Charles King III Economics 1997 Economics of the anti-ulcer drug market Harvard Business School
John Konz Chemical Engineering 1998 Effects of oxygen on recombinant protein expression
Kornelia KrajnyakEconomics1997Pharmaceutical industry structureInternational Monetary Fund
Michael Laska Chemical Engineering2000Benchmarking the manufacture of pharmaceuticals
Per Lindell Chemical Engineering 1992 Strategic issues in pharmaceutical manufacturing Boston Consulting Group
Gerald Lumer Economics 1995 Risk and return in pharmaceutical R&D U.S. Dept. of Justice
Michael Miller Operations Research 1996 Reexamining drug trials consulting
Mark MooreEconomics 1997Economics of industrial organization
Kaivan MunshiEconomics1995Investment behavior and financial structureBoston Univ.
Dept. of Economics
Gil Preuss Sloan School 1997 Human resource incentives and physicians' prescribing behavior
G.K. Raju Chemical Engineering 1997 Early involvement of FDA advisory committees to speed up the drug evaluation process MIT/CAMP
David ReilyEconomics1996The economics of a new industry: the diffusion of modern anti-ulcer drugsVanderbilt Univ.
Dept. of Marketing
Daniel RodriguezEconomics1997Economies of scale in the pharmaceutical industry
Fiona Scott MortonEconomics 1994 Barriers to entry, brand advertising, and generic entry in U.S. pharmaceutical industry Stanford Univ.
Grad. School of Business
Christoper VoiseySloan School 1998 Pharmaceutical R&D in the new environment
Stefan WeissflogChemical Engineering 1997Benchmarking the manufacture of pharmaceuticals academic position in Germany
R. Steven White Sloan School 1998 Pharmaceutical R&D project management

OTHER STUDENTS

Name

Department

Degree

Thesis Topic/Interest
Adi AlonSloan SchoolMSPioneering in the pharmaceutical industry
Tetsuya ArakiSloan SchoolMSJapan's pharmaceutical industry: Transformation in response to recent environmental change
Peter BittingerSloan SchoolMSThe effects of price and profit regulation on the international competitiveness of the pharmaceutical industry
Gary BrackenridgeSloan SchoolBSPublic-private interaction in pharmaceutical research
Sean CampbellSloan SchoolMSBenchmarking the manufacture of pharmaceuticals
Thomas FlanaganSloan SchoolMSManagement of clinical research
Roland FrankeSloan SchoolMSThe role of combinatorial chemistry in drug development
Christopher HoweSloan SchoolMBAFinancial modeling of drug R&D
Pai-Feng Paul HsuSloan SchoolMSOn the measurement of price-quality relationships in anti-hypertensive drugs using hedonic price analysis: A feasibility study
Shehla ImranEconomicsBSEconomies of scale in the pharmaceutical industry
Tim KapsSloan SchoolMSManaging and organizing for higher performance in drug development projects
Zhara KheraniEconomicsBSIntellectual property issues in biotechnology
Jong KimEconomicsBSGeneric entry and competition in the pharmaceutical industry
Peter LathamSloan SchoolMSBenchmarking the manufacture of pharmaceuticals
Steven LipariSloan SchoolMSA medical device as a new business opportunity
Michele LombardiElectrical Engineering
and Computer Science		BSMarketing issues for anti-ulcer therapy
Christophe MalaterreTechnology &
Policy		MSAn economic development strategy for the biotechnology industry in Massachusetts
Andrew McCraithMechanical EngineeringBSEconomies of scale in the pharmaceutical industry
Eyal MeltzerManagement of
Technology		MSThe order of entry of a drug and market share
Christine MooreChemical EngineeringMSStrategic issues in pharmaceutical manufacturing
Albert MoralesSloan SchoolMSBenchmarking pharmaceutical manufacturing
Jose PachecoEconomicsBSQuality adjusted pharmaceutical price indexes
Helen ParkBiologyBSIntellectual property issues
Andria PomponiChemistryBSBarriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry
Lisa ProsserSloan SchoolMSThe effect of increased competition on human resource strategies in pharmaceutical R&D
Paolo RadaelliManagement of TechnologyMSStrategic alliances among pharmaceutical firms
Jordan RubensonSloan SchoolMSThe emerging strategic role of manufacturing in the pharmaceutical industry
Bonnie ScoulerSloan SchoolMSA segmentation analysis of the ulcer drug market
John SwenSloan SchoolMSUse of IT by start-up biotechnology firms
Francois ThomasSloan SchoolMSOutsourcing research in the pharmaceutical industry
Matt VerlindenSloan SchoolMSThe effect on isolation technology on aseptic pharmaceutical processing technology
Jeffrey WilliamsSloan SchoolMSBenchmarking manufacturing costs in the biotechnology industry
Hyun-Sook WooSloan SchoolMSThe effect of project management structure on new drug development

Please send comments and suggestions to popi-www@mit.edu

[Back to POPI Home Page]